Yale University School of Medicine.

To identify heart failure hospitalization and 1-year mortality after HF hospitalization performed Jersey Chen, Yale University School of Medicine, New Haven, Connecticut, and his team have an investigation that involved data 55,390 persons fee-for – service Medicare, between 1998 and 2008 with a principal discharge diagnosis code for heart failure admitted to the hospital. Examined examined in the study of acute care hospitals in Puerto Rico and the U.S. During the investigation, the mean age for patients with heart failure increased from 79.0 years to 79, the ratio of female patients decreased from 58.9 percent to 55.7 percent and the ratio of black patients increased from 11.3 percent to 11.

After evaluating the data from 1998 to 2008, the researchers found a relative decrease of 29.5 percent in the total risk-adjusted heart failure hospitalization. In hospital. Heart failure hospitalizations decreased for all race – sex categories in the course of the study, although black men had the lowest rate of decline.Enzon Pharmaceuticals in.. On EZN-4176 EZN – 4176, is an androgen receptor mRNA antagonist, a Locked Nucleic Acid oligonucleotide to express modulating AR mRNA. In vitro EZN-4176 has been shown that downward modulates AR the mRNA and protein and inhibiting AR transcriptional activity and cell growth. AR will widely recognized as an important therapeutic destination for treatment of prostate cancer, much as androgens, prostate tumor growth and viability is. EZN-4176 are based on the proprietary LNA Enzon technology platform targets that were licensed by Santaris Pharma A / S, on the basis of the LNA technology permits are the antisense molecule as about highly effective resistance nuclease degradation and administering of the molecule if iv in physiologic saline solution prepared .

Enzon followed by beginning of this study , the presenting the preclinical data at the 2010 EORTC-NCI – AACR meetings demonstrated potent anti-tumor activity of EZN-4176, either alone or combined with MDV-3100, a novel AR receptor antagonist, be currently in Phase 3 testing.